Headquartered in Portage, MI Fiscal year ends December NYSE: SYK stryker.com
Stryker Corporation is a global medical technology company offering innovative products and services across its MedSurg and Neurotechnology and Orthopaedics segments. The MedSurg and Neurotechnology segment encompasses Instruments (including Neuro Cranial and Enabling Technologies), Endoscopy, Medical, and Vascular product lines. The Orthopaedics segment includes Knees, Hips, Trauma and Extremities, Ortho Tech (combining orthopaedic instruments and other orthopaedics products), and Spinal Implants. The company serves hospitals and healthcare providers worldwide, impacting more than 150 million patients annually. Stryker's products support surgical procedures, patient monitoring, and rehabilitation across a broad range of clinical specialties. Updated
A 26% price drop on a stock with a near-monopoly business model and 85% recurring revenue sounds like a warning, but one investor sees it as an invitation to keep buying.
Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder…
Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is quietly…
Intuitive Surgical is down more than 30% this year, and one investor keeps buying anyway, convinced that a once-per-decade hardware cycle and an $8.6 billion cash fortress make the drawdown a gift…
Intuitive Surgical has shed a third of its value while its robotic surgery peers barely flinched, and Wall Street's most bullish analyst sees an outcome that would leave anyone who sold near…
Intuitive Surgical just posted its fifth consecutive earnings beat and management started buying back shares above current prices, yet the stock sits at a level that implies something far worse than a…
Stryker (NYSE:SYK | SYK Price Prediction) and Intuitive Surgical (NASDAQ:ISRG) both closed the books on Q1 2026 with sharply different results. Stryker absorbed a March 11 cyberattack and heavy restructuring charges while…
Surgical robotics is quietly becoming an artificial intelligence story. Every robotic procedure generates structured video, kinematic, and outcomes data that platforms feed back into surgeon training, intraoperative guidance, and predictive analytics. That…
A medical technology company based in the United States, Stryker (NYSE:SYK | SYK Price Prediction) entered 2026 on the back of record Mako robotic installations and its first-ever $25 billion revenue year,…
David Beren Stryker (NYSE:SYK | SYK Price Prediction) is one of the quieter success stories in large-cap healthcare, and Reddit has barely noticed. Shares are down 9.46% over the past week, sitting at $337.29,…
Michael Williams Citi is making a clear statement about the health of U.S. medical technology heading into the spring: the sector’s fundamentals remain intact, even as broader market volatility has dragged down some of…
Pre-Market Stock Futures: The futures are little changed after a blockbuster day to open the first full trading week of 2026. The combination of no Santa Claus rally, the market shrugging off…
Pre-Market Stock Futures: Futures are trading higher on Friday as we prepare for the holiday-shortened week leading up to Christmas, following a solid risk-on Thursday. The Consumer Price Index print for November…
After years of a low-interest rate environment, which has reversed in a big way over the last 18 months, many investors continue to turn to equities not only for growth potential but…
Wednesday's top analyst upgrades and downgrades included American Express, Catalent, Centene, Lowe's Companies, NetApp, Shoals Technologies, Valley National Bancorp and ZoomInfo Technologies.
Stryker Corporation is a global medical technology company offering innovative products and services across its MedSurg and Neurotechnology and Orthopaedics segments.
24/7 Wall St.'s 12-month price target for SYK is $358.07, rated Buy. The Wall Street consensus target is $362.62. SYK price prediction →
